Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan + apatinib in soft tissue sarcoma after standard therapy failure
ChiCTR2600116806Phase 2Recruiting
- Sponsor
- First Medical Center of Chinese PLA General Hospital
- Start
- Jan 2026
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan and Rivoceranib in soft tissue sarcoma (STS), sponsored by First Medical Center of Chinese PLA General Hospital. Primary endpoint: Progression-free survival. Started Jan 2026; status: recruiting.
02
Drugs
nanoliposomal irinotecanRivoceranib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2600116806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116806.